AM3, an Oral BRM: Protective Agent against Iatrogenic Bone-Marrow and Liver Damage in Breast Cancer Patients under Conventional Adjuvant Radiochemotherapy
In five clinical trials AM3, a polysaccharide/protein biological response modifier, was given (3 g/day; two capsules, tid) to 79 breast cancer patients undergoing adjuvant radio- and/or chemotherapies. When compared with 68 control patients, AM3 provoked significant decreases in the incidence of bon...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Hindawi Limited
1992-01-01
|
| Series: | Canadian Journal of Infectious Diseases |
| Online Access: | http://dx.doi.org/10.1155/1992/917546 |